symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. vaccinated against covid19 infection. contraindications for nicotine patches: pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman lack of effective contraception for women of childbearing potential generalized skin conditions that can interfere with the use of a transdermal patch stroke or myocardial infarction or acute coronary syndrome for less than 3 months allergy to nicotine or to one of the excipients of the transdermal patch uncontrolled high blood pressure unstable or worsening angor severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) obliterating peripheral arterial disease known severe heart failure known severe renal or hepatic impairment, pheochromocytoma uncontrolled hyperthyroidism esophagitis due to gastroesophageal reflux disease or active peptic ulcer 7 already included in an interventional trial evaluating a health product 8 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 9 do not have a smartphone

symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. vaccinated against covid19 infection. contraindications for nicotine patches: pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman lack of effective contraception for women of childbearing potential generalized skin conditions that can interfere with the use of a transdermal patch stroke or myocardial infarction or acute coronary syndrome for less than 3 months allergy to nicotine or to one of the excipients of the transdermal patch uncontrolled high blood pressure unstable or worsening angor severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) obliterating peripheral arterial disease known severe heart failure known severe renal or hepatic impairment, pheochromocytoma uncontrolled hyperthyroidism esophagitis due to gastroesophageal reflux disease or active peptic ulcer 7 already included in an interventional trial evaluating a health product 8 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 9 do not have a smartphone

1. symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days 2. documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion 3. treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion 4. known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. 5. vaccinated against covid19 infection. 6. contraindications for nicotine patches: - pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman - lack of effective contraception for women of childbearing potential - generalized skin conditions that can interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angor - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - obliterating peripheral arterial disease - known severe heart failure - known severe renal or hepatic impairment, - pheochromocytoma - uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or active peptic ulcer 7 already included in an interventional trial evaluating a health product 8 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 9 do not have a smartphone

1. symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days 2. documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion 3. treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion 4. known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. 5. vaccinated against covid19 infection. 6. contraindications for nicotine patches: - pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman - lack of effective contraception for women of childbearing potential - generalized skin conditions that can interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angor - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - obliterating peripheral arterial disease - known severe heart failure - known severe renal or hepatic impairment, - pheochromocytoma - uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or active peptic ulcer 7 already included in an interventional trial evaluating a health product 8 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 9 do not have a smartphone

1. symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days 2. documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion 3. treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion 4. known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. 5. contraindications for nicotine patches: - pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman - lack of effective contraception for women of childbearing potential - generalized skin conditions that can interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angor - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - obliterating peripheral arterial disease - known severe heart failure - known severe renal or hepatic impairment, - pheochromocytoma - uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or active peptic ulcer 6 already included in an interventional trial evaluating a health product 7 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 8 do not have a smartphone

1. symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days 2. documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion 3. treatment ongoing with nicotine replacement therapy, varenicline or bupropion within 30 days before inclusion 4. known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. 5. contraindications for nicotine patches: - pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman - lack of effective contraception for women of childbearing potential - generalized skin conditions that can interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angor - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - obliterating peripheral arterial disease - known severe heart failure - known severe renal or hepatic impairment, - pheochromocytoma - uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or active peptic ulcer 6 already included in an interventional trial evaluating a health product 7 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 8 do not have a smartphone

1. symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days 2. documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion 3. treatment ongoing with nicotine replacement therapy, varenicline or bupropion 4. known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. 5. contraindications for nicotine patches: - pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman - lack of effective contraception for women of childbearing potential - generalized skin conditions that can interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angor - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - obliterating peripheral arterial disease - known severe heart failure - known severe renal or hepatic impairment, - pheochromocytoma - uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or active peptic ulcer 6 already included in an interventional trial evaluating a health product 7 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 8 do not have a smartphone

1. symptoms suggestive of covid-19 on the day of inclusion or in the past 14 days 2. documented history of covid-19 and / or positive sars-cov2 serology before the day of inclusion 3. treatment ongoing with nicotine replacement therapy, varenicline or bupropion 4. known addiction problem to alcohol (defined by audit-c > or = 10) or other substances. 5. contraindications for nicotine patches: - pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman - lack of effective contraception for women of childbearing potential - generalized skin conditions that can interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angor - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - obliterating peripheral arterial disease - known severe heart failure - known severe renal or hepatic impairment, - pheochromocytoma - uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or active peptic ulcer 6 already included in an interventional trial evaluating a health product 7 staff under guardianship or curatorship or deprived of their liberty by a judicial or administrative decision 8 do not have a smartphone